<div>
  <ul>
    <li>
      <p>
        Genetic testing and CDx tools provider Veracyte has completed its acquisition of genetic testing company C2i Genomics at a consideration of USD 70 million (subject to customary purchase price adjustments) paid through 2.7 million shares of Veracyte. An additional amount of up to USD 25 million is payable in cash or Veracyte shares at the buyer&rsquo;s election contingent on future performance relating to milestones over the next two years.
      </p>
    </li>
    <li>
      <p>
        Through the acquisition, Veracyte will add whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and augment its ability to serve patients across the cancer care continuum.
      </p>
    </li>
    <li>
      <p>
        Veracyte's initial application of C2i Genomics' technology is expected to involve a test for MRD in muscle-invasive bladder cancer by leveraging its urology commercial channel and a clear pathway to anticipated reimbursement. The company also intends to expand the development of additional MRD tests across various targeted indications.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://investor.veracyte.com/news-releases/news-release-details/veracyte-completes-acquisition-c2i-genomics">
      Press release
    </a>
  </p>
</div>


Precision Medicine

<div>
 <p>Veracyte, a provider of Genetic testing and CDx tools, has finalised its acquisition of genetic testing firm C2i Genomics. The deal concluded at a cost of USD 70 million paid through 2.7 million Veracyte shares. It also includes an additional payment of up to USD 25 million in cash or Veracyte shares, contingent on future achievements over the next two years.</p>
 <p>Through the purchase, Veracyte will extend its diagnostic platform with whole-genome minimal residual disease (MRD) capabilities. This development will enhance its capacity to cater to patients throughout the trajectory of cancer care.</p>
 <p>Veracyte plans to initially apply the technology from C2i Genomics for an MRD testing in muscle-invasive bladder cancer. This process will utilise its urology commercial channel and is expected to meet anticipated reimbursement. The firm also has plans for additional MRD test development for various targeted indications in the future.</p>
</div>

Veracyte acquires C2i Genomics to add whole-genome minimal residual disease capabilities to its diagnostics platform

Genetic testing firm Veracyte has acquired Israeli company C2i Genomics, a specialist in minimal residual disease (MRD) detection, in a deal worth $70 million, plus $25 million dependent on performance over two years. The deal allows Veracyte to add whole-genome MRD capabilities to its diagnostic platform and expand its cancer care offerings. Veracyte plans to apply C2i Genomics' technology to develop an MRD test for bladder cancer, initially leveraging existing urology commercial channels and a clear pathway to expected reimbursement. Further MRD tests in several other areas are planned.<div>

All Updates

Veracyte acquires C2i Genomics to add whole-genome minimal residual disease capabilities to its diagnostics platform

Veracyte Acquires C2i Genomics for USD 70 million with additional USD 25 million tied to performance over next two years